{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Lexaria Bioscience Corp."},"Symbol":{"label":"Symbol","value":"LEXX"},"Address":{"label":"Address","value":"740 MCCURDY ROAD,SUITE 100, KELOWNA, British Columbia, V1X 2P7, Canada"},"Phone":{"label":"Phone","value":"+1 250 765-6424"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio."},"CompanyUrl":{"label":"Company Url","value":"https://www.lexariabioscience.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Richard C. Christopher","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}